Medical education · Dr. William Abbott

19 May 2026 · Virtual · Dr. William Abbott, Universitätsklinikum Heidelberg · MSL Rachel Adeyemi · Vantrexa

ReviewedManualENG-0113—

Capture insight from this engagement

Location: Universitätsklinikum Heidelberg
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line
Sequencing after progression
Infusion-reaction management

Scientific content used

irAE management guide
VTX core scientific deck v3.2

Questions raised

How should grade 2 infusion reactions be managed without steroids?
Is there subgroup data for patients with untreated brain metastases?

Notes

Medical education with radiation oncologist at Universitätsklinikum Heidelberg. Discussed chemotherapy-free first line, sequencing after progression, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0113

Audit history (0)

All create, update and approval events for this record

No audit events in sample data